title: Results of radiation therapy for uterine cervical cancer using high dose rate remote after loading system.
abstract: In Japan, radiotherapy with high dose rate remote after loading system (HDR-RALS) for intracavitary brachytherapy is the standard treatment for more than 30 years. This report showed the usefulness of HDR-RALS for uterine cervical cancer. From 1980 through 1999, 442 patients with uterine cervical cancers (stage I: 66, stage II: 161, stage III: 165, stage IV: 50) were treated. Radiotherapy was performed both external teletherapy and HDR-RALS. Overall survival rate at 5 years was 60.2%. The 5-year actuarial incidence of all complications was 16.4%. The 5-year actuarial incidence of all complications in cases treated with the sum doses of whole pelvic irradiation (without central shield) and RALS up to 49 Gy, 50 to 59 Gy or larger doses were 7.5%, 11.0% and 25.2%, respectively. Radiation therapy using HDR-RALS was very effective. While the dose of whole pelvic irradiation was increased, the actuarial incidence of all complications was increased.
authors.affiliation: Department of Radiation Oncology, Tohoku University Graduate School of Medicine Sendai 980-8574, Japan. ogaway@rad.med.tohoku.ac.jp
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Nemoto
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kakuto
authors.forename: Hisanori
authors.initials: H
authors.lastname: Ariga
authors.forename: Haruo
authors.initials: H
authors.lastname: Matsushita
authors.forename: Ken
authors.initials: K
authors.lastname: Takeda
authors.forename: Chiaki
authors.initials: C
authors.lastname: Takahashi
authors.forename: Britton
authors.initials: B
authors.lastname: Gallardo
authors.forename: Keith
authors.initials: K
authors.lastname: Richard
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Takai
authors.forename: Shogo
authors.initials: S
authors.lastname: Yamada
mesh_terms: D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D018288:Carcinoma, Small Cell / Q000532:radiotherapy*; D004487:Edema / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007564:Japan; D008875:Middle Aged; D011829:Radiation Dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*; D014594:Uterine Neoplasms / Q000532:radiotherapy*